Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 3/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29386234 | 0.76 | TSHR (0.44) | TSHRTDP1HTR2AKDM1AMAOB | |
| SCHEMBL23855524 | 0.76 | TSHR (0.44) | TSHRTDP1HTR2AKDM1AMAOB | |
| SCHEMBL28442386 | 0.76 | TSHR (0.44) | TSHRTDP1HTR2AKDM1AMAOB | |
| SCHEMBL1721598 | 0.75 | TSHR (0.42) | TSHRTDP1HTR2AKDM1AMAOB | |
| SCHEMBL29674233 | 0.73 | HTR2A (0.47) | TSHRTDP1HTR2AKDM1AMAOB | |
| SCHEMBL22541598 | 0.73 | HTR2A (0.47) | TSHRTDP1HTR2AKDM1AMAOB | |
| SCHEMBL742364 | 0.72 | TSHR (0.48) | TSHRTDP1KDM1AMAOBAKR1B1 | |
| Hydrochloric Acid SCHEMBL7831784 | 0.70 | ADRA2A (0.45) | KDM1AMAOBHTR2C | |
| SCHEMBL14522963 | 0.69 | HTR2A (0.51) | TSHRTDP1HTR2AKDM1AMAOB | |
| SCHEMBL17778822 | 0.68 | SIGMAR1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2569310-A1 | MORPHOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | Pfizer Inc (US) | 2013-03-20 | — | — | EP | disclosed |
| US-20110281854-A1 | MORPHOLINE COMPOUNDS | PFIZER INC | 2011-11-17 | — | — | US | disclosed |
| WO-2011141848-A1 | MORPHOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281854-A1 | MORPHOLINE COMPOUNDS | REN, MC2R, NR3C2 | TSHR 412/4885TDP1 4444/4885HTR2A 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.